What conditions are treated with Sandostatin injections?
Sandostatin, also known as octreotide, is a medication used to treat various conditions, including acromegaly, carcinoid syndrome, and vasoactive intestinal peptide (VIP) tumors. It works by reducing the production of growth hormone and other hormones that contribute to these conditions [1].
Why are Sandostatin injections used in these conditions?
In acromegaly, Sandostatin injections help control the production of growth hormone, which can cause abnormal growth of body tissues and joints [2]. For carcinoid syndrome, the medication reduces the production of serotonin, a hormone that contributes to symptoms like flushing, diarrhea, and wheezing [3]. In VIP tumors, Sandostatin helps alleviate symptoms by decreasing the production of VIP, a hormone that causes excessive watery diarrhea and other symptoms.
What are the common side effects of Sandostatin injections?
Common side effects of Sandostatin injections include nausea, vomiting, diarrhea, and abdominal pain. Other possible side effects include injection site reactions, gallstones, and changes in blood sugar levels. It's essential to note that some patients may experience severe side effects, and patients should report any concerns to their healthcare provider [4].
Can people get Sandostatin injections through Biosimilar?
In the United States, there is a biosimilar version of Sandostatin, called Sandostatin LAR Depot (Octreotide acetate injection), which has been approved to treat acromegaly and carcinoid syndrome. While biosimilars can offer more affordable treatment options, they may have different formulations and dosing recommendations, so patients should consult with their healthcare provider to determine the best treatment plan [5].
When does the patent of Sandostatin expire?
According to DrugPatentWatch.com, the patent for Sandostatin (octreotide acetate injection) expires in various countries, with some expiring as early as 2017 and others expiring in 2026 [6].
References:
[1] DrugPatentWatch.com. (2023). Octreotide Acetate Injection.
[2] National Institutes of Health. (2020). Acromegaly. Retrieved from https://www.niddk.nih.gov/health-information/endocrine-diseases/acromegaly
[3] Gastrointestinal Society. (2020). Carcinoid Syndrome. Retrieved from https://www.gastrosociety.com/patient/conditions-and-treatment/caroid syndrome/
[4] Sandostatin.com. (2023). Common Adverse Reactions.
[5] FDA.gov. (2023). Sandostatin LAR Depot (Octreotide acetate injection).
[6] DrugPatentWatch.com. (2023). Octreotide Acetate Injection Patent.